Join this interactive roundtable to reshape how we measure and reward innovation in obesity therapeutics through cardiometabolic endpoints. As the field moves beyond weight loss alone, this session will bring together regulators, payers, clinicians, and patient advocates to align on new success metrics that reflect the full value of obesity treatments.

• Standardising evidence beyond BMI by aligning regulators and payers on multi-organ cardiometabolic benefits such as imaging data and body composition metrics as critical endpoints for approval and reimbursement
• Balancing clinical and patient priorities through trial designs that capture both hard outcomes like cardiovascular risk reduction and quality-of-life improvements in mobility and daily functioning
• Demonstrating compelling value to payers by modelling long-term economic benefits, including cost savings from comorbidity improvement in conditions like NAFLD and metabolic syndrome
• Exploring how RWE and comparator strategies can address fragmented EU HTA expectations, as well as what post-launch validation data payers are demanding